Longeveron Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LGVN research report →
Range $10 – $10
Price Chart
About the company
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses.
- CEO
- Stephen H. Willard
- IPO
- 2021
- Employees
- 38
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on LGVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.37M
- P/E
- -0.20
- Fwd P/E
- 0.07
- PEG
- -0.00
- P/S
- 4.61
- P/B
- 1.13
- EV/EBITDA
- 0.07
- Div Yield
- 0.00%
- Gross Margin
- 66.44%
- Op Margin
- -2020.77%
- Net Margin
- -1921.72%
- ROE
- -243.26%
- ROIC
- -399.02%
Latest fiscal year · YoY change
- Revenue
- $1.20M-49.9%
- Gross Profit
- $803.00K-57.4%
- Op Income
- $-23,287,000
- Net Income
- $-22,704,000-42.1%
- EPS
- $-12.90-20.6%
- OCF Growth
- -34.4%
- FCF Growth
- -27.1%
- 52W High
- $12.30
- 52W Low
- $1.31
- 50D MA
- $2.44
- 200D MA
- $6.38
- Beta
- -0.26
- RSI (14)
- 40
- Avg Volume
- 115.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Longeveron said its HLHS readout is due in September, while reiterating cash through Q4 2026 and emphasizing partnership potential if data are positive.· August 12, 2026
- ELPIS II top-line data in hypoplastic left heart syndrome are expected in mid-September, making it the key near-term catalyst.
- Management said FDA-aligned endpoints and the SAP have been incorporated, with no unresolved issues disclosed.
- Cash and cash equivalents were $10.1 million at June 30, 2026, and management expects runway into Q4 2026.
- The company highlighted external validation from publications in Nature Medicine and Cell Stem Cell, plus its selection as an XPRIZE HealthSpan finalist.
- Management repeatedly framed a positive HLHS readout as a potential trigger for partnership discussions and a possible BLA path.
Revenue for the three months ended June 30, 2026 was $0.3 million, down $29 thousand or 10% versus the prior year period, mainly due to the absence of contract manufacturing revenue. General and administrative expense was $3.2 million, up $600 thousand or 23%, and research and development expense was $3.2 million, up $200 thousand or 7% due to higher clinical trial costs tied to ELPIS II. Net loss was $6.1 million versus $5.0 million a year ago, and cash and cash equivalents were $10.1 million at June 30, 2026. Management said that current cash is expected to fund operating expenses and capital expenditures into the fourth quarter of 2026. No formal full-year revenue or EPS guidance was given.
Stephen Willard described the company as entering an “incredibly important and exciting time,” centered on multiple potentially transformative milestones across its four stem cell therapy programs. He emphasized the mid-September ELPIS II readout, said a positive result could open the door to partnerships, and argued that partnering with established pharma would be the most efficient path to unlock asset value. His tone was optimistic and deal-oriented, with repeated references to external validation, manufacturing readiness, and commercialization potential.
Marie Washburn focused on the quarter’s financials and runway. She cited revenue of $0.3 million, G&A of $3.2 million, R&D of $3.2 million, and a net loss of $6.1 million, then noted cash and cash equivalents of $10.1 million as of June 30, 2026. She said the company expects current cash to fund operations and capital expenditures into the fourth quarter of 2026 under the current budget.
Analysts pressed management on the SAP/FDA alignment, the timing shift from August to September, and what data package could support a BLA if some primary or exploratory endpoints miss. Management said FDA feedback had already been incorporated into the statistical plan, that the slip to September was driven by a delayed last patient/last visit MRI milestone, and that there are no unresolved SAP issues. On approval strategy, management said event-based endpoints such as mortality, transplant-free survival, and hospitalizations could still support regulatory pathways, and that the company believes it will have sufficient survival data in September for long-term outcomes to inform next steps. Questions also covered manufacturing/CMC readiness and pricing; management said CMC progress has been strong and that partner discussions could help shape pricing and commercialization.
The company is close to a major HLHS data readout, and management sounded confident that the SAP, FDA interactions, and trial database timing are all under control. They also pointed to long-term survival data, external validation, XPRIZE recognition, and partnership interest as signs that a positive readout could materially improve the development and commercialization outlook.
The business remains loss-making, with only $10.1 million in cash and a runway guided only into Q4 2026. The core risk is that the upcoming ELPIS II readout may not be strong enough on the most important endpoints, and management repeatedly framed regulatory and commercial plans as dependent on favorable data and future partnerships.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.9%
- Shares Outstanding
- 3.23M
- Float Shares
- 2.36M
of shares held by institutions
39 13F filers
Buy/sell ratio 2.60. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Millennium Management LLC | 1.35M | ▲ 907.16K |
| Logos Global Management LP | 1.29M | ▲ 1.29M |
| Vanguard Group Inc | 499.13K | ▼ 6.45K |
| Adar1 Capital Management, LLC | 108.41K | ▼ 91.59K |
| Beacon Pointe Advisors, LLC | 100.00K | 0 |
| Virtu Financial LLC | 58.58K | ▲ 58.58K |
| Two Sigma Securities, LLC | 55.97K | ▲ 55.97K |
| Northern Trust Corp | 43.30K | ▲ 23.52K |
| Xtx Topco Ltd | 20.56K | ▲ 20.56K |
| Tower Research Capital LLC (Trc) | 8.42K | ▲ 8.42K |
| Mcguire Capital Advisors Inc | 4.00K | 0 |
| Allied Private Wealth LLC | 1.42K | ▲ 1.42K |
Held by 19 ETFs
Biggest fund positions in LGVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Jhaveri Nirav S. | other | 742 |
| Oct 1, 26 | Willard Stephen H | other | 1,987 |
| Oct 1, 26 | Agafonova Nataliya | other | 2,913 |
| Oct 1, 26 | Lehr Paul T | other | 2,253 |
| Oct 1, 26 | Blass Devin | other | 2,520 |
| Aug 17, 26 | Jhaveri Nirav S. | other | 300,000 |
| Aug 17, 26 | Jhaveri Nirav S. | other | 0 |
| Aug 19, 26 | Lehr Paul T | other | 286,000 |
| Aug 19, 26 | Hajjar Roger Joseph | other | 36,000 |
| Aug 19, 26 | Soffer Rock | other | 36,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LGVN coverage
Recent articles, reports, and earnings notes.
No research on LGVN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LGVN report →Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
globenewswire.com · Nov 12
Longeveron Announces Engagement of Lucid Capital Markets
globenewswire.com · Oct 28
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
globenewswire.com · Oct 26
Longeveron to Participate in Three Longevity/Aging Investment Conferences
globenewswire.com · Sep 30
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
reuters.com · Sep 16
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
globenewswire.com · Sep 16
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 3
Longeveron Announces 1-for-10 Reverse Stock Split
globenewswire.com · Aug 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.